

	Rs. lacs
	<b>Quarter ended 30-09-2017</b>
	(Unaudited)
<b>I. Income</b>	
Revenue from operations	6,273.50
Other income	147.06
<b>Total revenue</b>	<b>6,420.56</b>
<b>II. Expenses</b>	
Cost of materials consumed	2,909.63
Purchase of stock in trade	226.13
Changes in inventories of finished goods and work-in-progress	(157.82)
Employee benefits expense	1,062.25
Finance costs	290.99
Depreciation and amortisation expense	237.05
Other expenses	1,449.19
<b>Total expenses</b>	<b>6,017.42</b>
<b>III. Profit / (loss) before tax</b>	<b>403.14</b>
<b>IV. Tax (expense)/Credit</b>	
Current Tax - Minimum Alternate Tax payable	(88.68)
Less: Minimum alternative tax credit entitlement	40.97
<b>Net Current Tax (Expense)/Credit</b>	<b>(47.71)</b>
Deferred Tax (Expense)/Income	(66.39)
<b>Total tax (expense)/Credit (net)</b>	<b>(114.10)</b>
<b>V. Net Profit/(Loss) for the period</b>	<b>289.04</b>
<b>VI. Paid-up equity share capital of Rs.10 each</b>	<b>805.98</b>
<b>VII. Earnings per share (nominal value of share Rs. 10) (not annualised)</b>	
Basic ( In Rs.)	3.59
Diluted ( In Rs.)	3.56

**NOTES :**

1. This result is prepared in connection with the direct listing of the Company to be filed with the BSE Limited (BSE) or may be shared with and relied on as necessary by the Merchant Bankers duly appointed in this regard or any other regulatory authority in connection with the direct listing.
2. The Company has received notice from BSE Limited (BSE) whereby the Company has been provided with an option to either complete the procedures for direct listing of its equity shares on nationwide stock exchange or provide exit to public shareholders by acquiring their equity shares at rates determined by independent valuer. Pursuant to receipt of such notice, the Company has initiated the procedures for direct listing of its equity shares on BSE.
3. **Basis of Accounting :-** As per the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), the Company is required to follow and prepare its financial statements in accordance with the Ind AS with effect from 1 April 2017. However, for the purpose referred in note 1 above, the above financial results have been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standards specified under Companies (Accounting Standard) Amendment Rules 2016, which is in line with the accounting policies adopted in preparation of financial statements for the financial year ended 31 March 2017. Further, the above financial results has been prepared with the purpose of summarizing performance of the Company for the three months period from 1 July 2017 to 30 September 2017. Accordingly, comparable figures for any of the previous periods have not been considered in above statement.
4. The above results were approved by the Audit Committee and were thereafter approved by the Board of Directors of the Company on 17 November 2017.
5. The operations of the Company represent a single primary business segment relating to pharmaceuticals.

For and on behalf of the board of directors of Zim Laboratories Limited

  
Ahwar S. Daud  
Managing Director

  
Zulfiqar M. Kamal  
Director & CFO

Place: Nagpur  
Date: 17 November 2017